Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and c (Q42621178)

From Wikidata

Jump to navigation Jump to search

scientific article published on 15 May 2009

Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and co

Language	Label	Description	Also known as
English	Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and c	scientific article published on 15 May 2009	Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and co

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and c (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

1

object named as

Hisao Ogawa

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

author name string

Shokei Kim-Mitsuyama

2

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Tomio Jinnouchi

3

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Kunihiko Matsui

4

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Kikuo Arakawa

5

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

publication date

15 May 2009

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Hypertension Research

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

32

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

575-580

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

https://scigraph.springernature.com/pub.10.1038/hr.2009.60

0 references

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.60

21 January 2018

Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.60

21 January 2018

Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial.

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.60

21 January 2018

The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.60

21 January 2018

Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES).

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.60

21 January 2018

Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.60

21 January 2018

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.60

21 January 2018

Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.60

21 January 2018

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.60

21 January 2018

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.60

21 January 2018

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.60

21 January 2018

2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.60

21 January 2018

Clinical studies of CS-866, the newest angiotensin II receptor antagonist

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.60

21 January 2018

Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.60

21 January 2018

A Multiple Testing Procedure for Clinical Trials

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.60

21 January 2018

Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.60

21 January 2018

Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative Group.

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.60

21 January 2018

The optimal target blood pressure for antihypertensive treatment in Japanese elderly patients with high-risk hypertension: a subanalysis of the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.60

21 January 2018

Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.60

21 January 2018

Beneficial effects of combined blockade of ACE and AT1 receptor on intimal hyperplasia in balloon-injured rat artery

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.60

21 January 2018

Additive beneficial effects of the combination of a calcium channel blocker and an angiotensin blocker on a hypertensive rat-heart failure model

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.60

21 January 2018

Pravastatin enhances beneficial effects of olmesartan on vascular injury of salt-sensitive hypertensive rats, via pleiotropic effects.

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.60

21 January 2018

Olmesartan prevents cardiovascular injury and hepatic steatosis in obesity and diabetes, accompanied by apoptosis signal regulating kinase-1 inhibition

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.60

21 January 2018

Azelnidipine and amlodipine: a comparison of their pharmacokinetics and effects on ambulatory blood pressure

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.60

21 January 2018

Heart rate and the cardiovascular risk

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.60

21 January 2018

Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2004)

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.60

7 January 2021

based on heuristic

inferred from DOI database lookup

Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.60

7 January 2021

based on heuristic

inferred from DOI database lookup

Shanghai trial of nifedipine in the elderly (STONE)

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.60

7 January 2021

based on heuristic

inferred from DOI database lookup

Influence of heart rate on mortality among persons with hypertension: the Framingham Study

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.60

7 January 2021

based on heuristic

inferred from DOI database lookup

Enhancement of cardiac oxidative stress by tachycardia and its critical role in cardiac hypertrophy and fibrosis

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.60

7 January 2021

based on heuristic

inferred from DOI database lookup

Additional renoprotective effects of azelnidipine combined with angiotensin receptor blockers in patients with diabetic nephropathy.

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.60

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/HR.2009.60

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42621178&oldid=1836203199"